Clinical and haematological consequences of recurrent G6PD mutations and a single new mutation causing chronic nonspherocytic haemolytic anaemia |
| |
Authors: | Tom J. Vulliamy,Jaspal S. Kaeda,Dahlila Ait-Chafa,Rosa Mangerini,David Roper,Jose Barbot,Athul B. Mehta,Athanassiou-Metaxa,Lucio Luzzatto,& Philip J. Mason |
| |
Affiliation: | Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, U.K.,;Dipartimento di Oncologia Clinica e Sperimentale, Universitádi Genova and Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy,;Minesterio da Saude, Hospital Central Especializado de Criancas Maria Pia, Porto, Portugal,;Department of Haematology, Royal Free Hospital, London, U.K.,;First Paediatric Clinic, University of Thessaloniki, Greece,;Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, U.S.A. |
| |
Abstract: | We have determined the causative mutation in 12 cases of glucose-6-phosphate dehydrogenase deficiency associated with chronic non-spherocytic haemolytic anaemia. In 11 of them the mutation we found had been previously reported in unrelated individuals. These mutations comprise seven different missense mutations and a 24 base pair deletion, G6PD Nara, previously found in a Japanese boy. Repeated findings of the same mutations suggests that a limited number of amino acid changes can produce the CNSHA phenotype and be compatible with normal development. The one new mutation we have found, G6PD Serres, is 1082 C → T causing a 361 Ala → Val substitution in the dimer interface where most other severe G6PD mutations are found. Now that several patients with the same mutation have been reported we can compare the resulting clinical phenotypes. For each mutation we find a reasonably consistent clinical picture, ranging from mild (G6PD Clinic) through moderate (G6PD Nashville) to severe (G6PD Beverly Hills and G6PD Nara). |
| |
Keywords: | G6PD deficiency recurrent mutation G6PD Serres |
|
|